Twist Bioscience Quarterly Cash Flow Statement
NASDAQ: TWSTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Twist Bioscience free cash flow
In the quarter ended Jun 30, 2026, Twist Bioscience generated $1.1 million of operating cash flow and spent $9.8 million on capital expenditures. That left free cash flow of -$8.6 million, a free-cash-flow margin of -7.3% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Twist Bioscience cash flow statement (quarterly)
| Quarter (USD) | Q3 20262026-06-30 | Q2 20262026-03-31 | Q1 20262025-12-31 | Q4 20252025-09-30 | Q3 20252025-06-30 | Q2 20252025-03-31 | Q1 20252024-12-31 | Q4 20242024-09-30 | Q3 20242024-06-30 | Q2 20242024-03-31 | Q1 20242023-12-31 | Q4 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -35.05M | -44.02M | -30.51M | -27.14M | 20.39M | -39.33M | -31.59M | -34.66M | -85.57M | -45.49M | -43.01M | -46.24M |
| Net Income growth (YoY) | -271.90% | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 6.78M | 6.41M | 6.19M | 6.00M | 6.07M | 6.40M | 6.38M | 6.66M | 8.30M | 8.30M | 8.17M | 8.50M |
| Stock-Based Compensation | 18.18M | 18.94M | 13.27M | 16.08M | 16.06M | 20.33M | 11.99M | 12.35M | 13.73M | 13.82M | 11.02M | 11.75M |
| Change in Working Capital | 208.00K | -25.89M | -2.74M | -10.62M | -360.00K | -4.29M | 884.00K | -3.33M | 5.66M | -2.05M | 2.41M | 262.00K |
| Operating Cash Flow | 1.11M | -17.56M | -24.81M | -11.81M | -1.40M | -12.99M | -21.43M | -15.32M | -6.38M | -19.42M | -22.97M | -20.70M |
| Capital Expenditures | -9.76M | -7.89M | -9.97M | -12.43M | -9.16M | -4.14M | -2.27M | -2.00M | -965.00K | -603.00K | -1.51M | -2.39M |
| Investing Cash Flow | -10.20M | -12.71M | -9.93M | -12.40M | -9.40M | -1.43M | -1.54M | -1.28M | -711.00K | -5.24M | 4.17M | -2.25M |
| Debt Repaid | — | — | — | — | — | — | — | — | — | — | — | 0 |
| Financing Cash Flow | 3.79M | 4.14M | 298.00K | 5.57M | 1.83M | 3.20M | 17.94M | 3.63M | 2.91M | 1.83M | -1.47M | 442.00K |
| Net Change in Cash | -5.29M | -26.13M | -34.44M | -18.48M | -9.04M | -11.11M | -5.07M | -12.90M | -4.18M | -22.90M | -20.16M | -22.56M |
| Free Cash Flow | -8.65M | -25.45M | -34.79M | -24.24M | -10.56M | -17.13M | -23.70M | -17.32M | -7.34M | -20.03M | -24.48M | -23.10M |
This table shows 12 quarterly periods of Twist Bioscience's cash flow statement, from Q3 2026 back to Q4 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TWST's reporting calendar. What is a cash flow statement?